Good news but nothing that is going to move the stock as there are still financial issues that have this company trapped for a while. More pain and no gain AMBS. But that's what is par for the course for this mismanaged company.
On a side note, I wonder if Lonza will end up getting back into bed with ESS by partnering with AMBS once trials show success. It would make sense for them from my vantage point.
(1)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links